Author: Editor

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Nurse Leadership Board Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Nurse Leadership Board #1 Cont. Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Nurse Leadership Board Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses the use of genomic tests as predictive tools for adjuvant chemotherapy benefit in the management of patients with breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, explains the development of multigene tests, such as the Oncotype DX® Breast Cancer Assay and the PAM50 test, for classifying breast cancer into different subtypes. Luminal A and B subtypes of breast cancer may have important predictive value in the clinic. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses CheckMate 067, a randomised, double-blind, phase 3 trial of nivolumab monotherapy or nivolumab combined with ipilimumab versus ipilimumab monotherapy in patients with previously untreated unresectable or metastatic melanoma.

Since 2003, the IMF has honored an outstanding physician each year with the Robert A. Kyle Lifetime Achievement Award. The award, named for its first recipient, is presented to an individual whose body of work in the field of myeloma has made significant advances in research, treatment and care of myeloma patients. Our honorees work reflects the words of Dr. William Mayo, founder of Mayo Clinic, who challenged the nature of patient care nearly a century ago when he said The needs of the patient are the only needs to be considered. Visit our website at: http://www.myeloma.org Find us online:…

The International Myeloma Foundation (IMF) and the EuroFlow consortium introduce a new automated and highly sensitive flow cytometry method for standardized detection of minimal residual disease (MRD) in myeloma patients.

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the interim analysis of PROCEDE?1000, a prospective registry evaluating the impact of Prolaris®, a cell cycle progression (CCP) test, on personalising treatment decisions following biopsy in newly diagnosed patients with prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a randomised, phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib combined with everolimus in patients with metastatic renal cell carcinoma.

BRCA1 and 2 mutation carriers: breast cancer and more. Dr Shani Paluch-Shimon (Israel) discusses the topic with Dr Fedro A. Peccatori (Italy)

HPV vaccination for cervical cancer: times they are a-changing. Dr Xavier Bosch (Spain) explains the effectiveness of HPV vaccination. Discussion is lead by Dr Fedro A. Peccatori (Italy)

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, reviews the clinical development of new chemotherapy-based approaches for the management of patients with advanced prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, reviews the development of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) signalling pathway and the identification of predictive biomarkers of response to immunotherapies for the management of patients with lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, considers the impact of available and emerging targeted therapies and immunotherapies on the current treatment landscape in melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola Landgren, and Paul Richardson discusses the following topics: Diagnostic Criteria Revised ISS staging and personalized medicine MRD testing/response criteria The challenge of double refractory disease Drug costs and access: 2015 and beyond Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola Landgren, and Paul Richardson discusses the following topics: Diagnostic Criteria Revised ISS staging and personalized medicine MRD testing/response criteria The challenge of double refractory disease Drug costs and access: 2015 and beyond Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola Landgren, and Paul Richardson discusses the following topics: Diagnostic Criteria Revised ISS staging and personalized medicine MRD testing/response criteria The challenge of double refractory disease Drug costs and access: 2015 and beyond Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola Landgren, and Paul Richardson discusses the following topics: Diagnostic Criteria Revised ISS staging and personalized medicine MRD testing/response criteria The challenge of double refractory disease Drug costs and access: 2015 and beyond Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd) Support the IMF! http://bit.ly/WskQHC

IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd) Support the IMF! http://bit.ly/WskQHC

In this week’s video, Dr. Brian Durie discusses Selinexor, a novel, orally administered drug that is currently ongoing clinical trials. Bottom Line: Selinexor is a promising new type of drug that can make a difference for myeloma patients. Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

In this weeks video, Dr. Brian Durie gives an update on the IMFs signature research project, Black Swan Research Initative. Bottom Line: The BSRI team is expanding worldwide and exciting progress is being made.

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the interim analysis of the randomised, double-blind, placebo-controlled, phase 3 HELIOS trial, which evaluated ibrutinib, a Bruton’s tyrosine kinase inhibitor, combined with bendamustine and rituximab (BR) versus vs BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of ENDEAVOR, a randomised, open-label, phase 3 trial comparing carfilzomib plus dexamethasone versus bortezomib plus dexamethasone in patients with relapsed multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides an update on IMAAGEN, a multicentre, open-label, single-arm, phase 2 trial evaluating the effect of abiraterone acetate plus prednisone on prostate specific antigen and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer without radiographic evidence of metastatic disease. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, discusses ASCO’s Conquer Cancer Foundation, which was set up to improve cancer care by funding research, sharing knowledge worldwide and supporting access to treatments. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia from the phase 3 RESONATE trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, explains that the development of immunotherapies for a variety of cancer types and specific cancer proteins is a very active area of research at Sarah Cannon Research Institute. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses current research into treatments that target mechanistic events in the development of melanoma, and how the results of such research can be applied in the clinic. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Learn more about current trends in myeloma treatment and research with this update from three major medical meetings held in June 2015. Dr. Brian G.M. Durie will explain what’s new and exciting from the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG). Go to www.2015ASCOrecap.myeloma.org to download the slides used in the teleconference.

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides an update on the CALGB/CTSU/Alliance 49907 trial, which compared capecitabine with standard chemotherapy in patients with breast cancer who were at least 65 years old. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic, discusses new data that support earlier treatment of patients with mantle cell lymphoma (MCL), including the results of an investigation of a bortezomib-based regimen as frontline therapy for patients with newly diagnosed MCL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, reviews the progress of biomarker discovery and validation for informing clinical decision-making in the management of patients with prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Masakazu Toi, MD, PhD, of Kyoto University, Japan, explains that there are still only limited data available regarding the genomic profile of breast tumours in Japanese patients. Information gained from pathological assessment and multigene assays, such as the Oncotype DX® Breast Cancer Assay and MammaPrint, needs to be compiled to further understand breast cancer as a disease and to determine how molecular profiling can be applied in the clinic. In Japan, multigene assays for breast cancer are not currently part of the healthcare system. However, Dr Toi believes that these…

Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options. For more information, visit: http://www.cancertypeid.com

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure patient access and cost reimbursement. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses clinical trials of new treatments for Hodgkin lymphoma (HL). Topics of interest include bendamustine-containing regimen (BeGEV) as induction chemotherapy prior to autologous stem cell transplantation for patients with relapsed or refractory HL and the phase 1 trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for elderly patients with HL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses promising monoclonal antibodies in clinical development for the treatment of patients with multiple myeloma. Prof Lonial focuses on the basic and clinical aspects of several novel monoclonal antibodies, including daratumumab, which targets CD38, and elotuzumab, which targets signalling lymphocytic activation molecule-F7 (SLAMF7). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Kidney Test

Dr. Geo Espinosa of NYU Langone Medical Center talks about the holistic approach in patient care in Integrative Urology which combines traditional therapies and complementary medicine for maximum patient benefit.

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer Index (BCI) and its impact on patient confidence in their treatment plan. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the randomised controlled phase 2 Borealis-1 trial, which evaluated the efficacy and safety of gemcitabine and cisplatin with and without apatorsen, a novel antisense oligonucleotide that inhibits heat shock protein 27 (Hsp27) production, in patients with metastatic bladder cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2 trial, which is a multicentre, randomised phase 3 trial comparing the efficacy and safety of pacritinib versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, provides an overview of promising novel immunotherapeutic strategies that are currently under investigation for the treatment of patients with kidney cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, discusses the results of the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, discusses the ongoing phase 3 ARAMIS trial, which is evaluating the efficacy and safety of the novel androgen receptor inhibitor, ODM-201, in men with high-risk non-metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that evaluated the safety and efficacy of the PI3K? inhibitor, idelalisib, in combination with chemoimmunotherapy for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Investigated combinations include idelalisib in combination with rituximab; ofatumumab; bendamustine and rituximab; fludarabine; and chlorambucil. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC, discusses the results of the double-blind, phase 3 PALOMA-3 trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicentre phase 2 study, which is evaluating brentuximab vedotin plus adriamycin, vinblastine and dacarbazine (AVD) for patients with non-bulky limited-stage Hodgkin lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, summarises the concept of precision medicine in cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune responses and clinical outcomes in STAND, a randomised phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer after local therapy failure. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lodovico Balducci, MD, of Moffitt Cancer Center, Tampa, FL, explains the current landscape and unmet clinical needs in geriatric oncology. Older patients have highly variable physiologic ages, so there is an increasing emphasis on individualising treatment to optimise clinical outcomes. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses the median progression-free survival (PFS) evaluation and correlative biomarker analysis from coBRIM, a phase 3 study of cobimetinib plus vemurafenib in patients with advanced BRAF-mutated melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, discusses the increasing focus on physiological factors in preference to chronological age in determining optimal treatment decisions in older patients with breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® a number ranging from 0 to 100. This number indicates the likelihood that a woman’s breast cancer will spread to another area of her body within 10 years of her initial diagnosis. The lower the score is, the lower the chances are that the woman’s breast cancer will come back. The higher the score is, the greater the chances that the breast cancer will come back. Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the Recurrence…

Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer Index (BCI) in treatment decision making. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice. For more information, visit: http://www.cancertypeid.com

At the 9th European Breast Cancer Conference (EBCC), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, and Daniel Rea, MBBS, BSc, PhD, FRCP, of the University of Birmingham, Birmingham, United Kingdom, UK, discuss the molecular diversity of breast cancer. They explain that patients with breast cancer can be categorised using molecular tools to help guide clinical decision-making. Focusing on giving clinicians practical advice for the consultation room, they review the results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey, which evaluated patient attributes and clinician attitudes considered for decision-making with regard to adjuvant chemotherapy in early…

Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, disusses the results of the CheckMate 067 trial, a phase 3 trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma. NIVO combined with IPI and NIVO alone had superior clinical activity versus IPI alone. The results with NIVO combined with IPI and NIVO alone further suggest complementary activity of the two agents. There were no new safety signals or drug-related deaths observed with the combination. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains the Oncotype DX® Breast Cancer Assay and how it is performed, detailing the specificities of the test and how the Recurrence Score® result is reported. She highlights how her multidisciplinary team chooses to use a genomic test, such as the Oncotype DX assay, to guide adjuvant chemotherapy decisions in luminal breast cancers. She comments on the use of the Oncotype DX assay with traditional markers and other markers such as ER, PR or HER2. The Recurrence Score result is complementary for select patients. Her…

Anne Armstrong, MRCP, PhD, MB ChB, BSc(Hons), of The Christie Hospital, Manchester, UK, and Nigel Bundred, MD, FRCS, of The University of Manchester, UK, discuss genomic profiling for patients with breast cancer and the Oncotype DX® Breast Cancer Assay. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her experience on the recommended treatment approach for oestrogen receptor (ER)-positive, HER2-negative breast cancer patients. Prof Rugo comments on the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumour. She also comments on the use of criteria, such as tumour grade and size, to select patients for adjuvant chemotherapy as well as the usage of immunohistochemistry (IHC) markers, such as hormone receptor markers, to identify…

Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility. For more information, visit: http://www.cancertypeid.com

Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer Index (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer Research and Royal Marsden Hospital, London, UK, discusses the results of the double-blind, phase 3 PALOMA3 trial of fulvestrant with or without the novel cyclin-dependent kinase 4/6 inhibitor, palbociclib, in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who progressed on prior endocrine therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the recent progress in understanding clinically relevant genomic alterations in kidney cancer. Genomic profiling of collecting duct carcinomas, a rare kidney cancer subtype, revealed a high frequency of NF2 genomic alterations, which may represent opportunities for the application of targeted therapies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the recent development of molecularly targeted therapies in the management of haematological malignancies. Emerging targeted agents include monoclonal antibody (mAb) targeting Signaling Lymphocytic Activation Molecule F7 (SLAMF7), elotuzumab, for multiple myeloma; anti-CD38 mAb, daratumumab, for multiple myeloma; anti-CD20 mAb, obinutuzumab, for chronic lymphocytic leukaemia (CLL); and ibrutinib plus bendamustine for CLL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting on new treatments for patients with multiple myeloma. Topics of interest include chimeric antigen receptor (CAR) T-cell therapy, the anti-CS1 humanised monoclonal antibody, elotuzumab, lenalidomide maintenance therapy, first-line treatment of newly diagnosed multiple myeloma using lenalidomide plus dexamethasone, and the histone deacetylase (HDAC) inhibitor, panobinostat. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune response from STRIDE, a randomised, phase 2, open-label trial of sipuleucel-T with concurrent versus sequential enzalutamide administration in patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, describes ASCO’s initiatives for the upcoming year. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer Index (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy. For more information, visit: http://www.cancertypeid.com

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, reviews the results of the phase 3 CheckMate 067 trial of nivolumab in treatment-naive patients with advanced melanoma, and the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Jacqueline Barrientos, MD, summarises recent progress in the treatment of chronic lymphocytic leukaemia at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. He highlights trials on combined BRAF and MEK inhibition versus BRAF inhibition alone, and immunotherapy drug combinations. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naive patients with advanced melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses the results of the randomised, double-blinded, phase 3 COMBI-d trial, which compared the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Andrew B. Lassman, MD, of Columbia University Medical Center, New York, NY, discusses the results of the randomised phase 3 NCCTG N0574 (Alliance) trial of whole brain radiation therapy in addition to stereotactic radiosurgery in patients with 1 to 3 brain metastases. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, provides an overview of the current unmet needs in the treatment of metastatic kidney cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium, discusses the results of a randomised, open-label, multicentre, phase 3 trial of the microtubule dynamics inhibitor, eribulin, versus dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Michael J. Mauro, MD, provides a summary of the SIMPLICITY trial. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.

Stuart L. Goldberg, MD provides CML meeting highlights live from the 2015 ASCO Annual Meeting that significantly impact practice. For additional meeting highlights from other congresses, http://managingcml.com/con-ed-cml/annual-meeting-highlights-cml For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.

Dr. Karen Seiter discusses the efficacy and safety considerations in using ponatinib. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.

Dr. Karen Seiter discusses the most common reasons for treatment failur For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.

Dr. Karen Seiter discusses using second-generation TKIs as a first-line approach. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.

Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lenvatinib is an oral tyrosine kinase inhibitor of the VEGFR13, FGFR14, PDGFR?, RET, and KIT signaling networks. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results of the multi-arm phase 1 TATTON trial, which evaluated the mutant-selective EGFR tyrosine kinase inhibitor, AZD9291, combined with MEDI4736 (anti-PD-L1 monoclonal antibody), savolitinib (MET inhibitor) or selumetinib (MEK1/2 inhibitor) in patients with EGFR-mutant lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Is there a role for second-line therapy in advanced pancreatic cancer? For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.

Dr. Koushik Das discusses the type of patients that would benefit from pancreatic cancer screening. For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.

Dr. Koushik Das discusses screening tests and predictive biomarkers for pancreatic cancer. For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.

Dr. Jill Lacy discusses radiotherapy in the treatment of pancreatic cancer, how its role is evolving in specific settings, and when and how to use radiotherapy in pancreatic cancer. For more information, tools, resources and CE activities please partnersinpancreaticcancer.com Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.

Dr. Jill Lacy discusses the development of immune therapies for pancreas cancer, the progress that is being made, and provides an update on CRS-207 and GVAX.

At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 multicentre, randomised, open-label MCL-002 (SPRINT) trial of lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, versus investigators choice (chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab) in patients with relapsed/refractory mantle cell lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses ongoing clinical studies by the German CLL Study Group (GCLLSG) that are investigating new therapies for patients with chronic lymphocytic leukaemia (CLL), including obinutuzumab in combination with chlorambucil; a watch-and-wait strategy; and a four-arm study comparing standard chemotherapy versus non-chemotherapy-containing regimens. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the first results from the phase 3 HELIOS trial, which evaluated the first-in-class, oral covalent Bruton’s tyrosine kinase inhibitor, ibrutinib, in combination with bendamustine and rituximab (BR) versus BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label, randomised phase 3 ENDEAVOR study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the results of the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study. EXELS study is an observational phase 4 study that compared safety, pregnancy outcomes, and efficacy (measured by incidence of thrombohaemorrhagic events and platelet reduction) of anagrelide compared with other cytoreductive therapies in high-risk patients with essential thrombocythemia (ET). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Breast Cancer Index (BCI) is a molecular, gene expression-based test uniquely positioned to identify patients best suited for extended endocrine treatment. It is the only validated, commercially available test that provides prognostic risk of late recurrence (5-10 years post-diagnosis), as well as prediction of extended endocrine therapy benefit. The breakthrough test helps oncologists and patients navigate the difficult trade-off between wanting to take steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to extended endocrine therapy. Breast Cancer Index (BCI) was granted Medicare coverage in October 2014. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com…

Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies. For more information, visit: http://www.cancertypeid.com

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses the trial design and results of the phase 3 PERSIST-1 trial of pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses follow-up data of the RESPONSE trial, which is a multicentre, open-label phase 3 study evaluating the efficacy and safety of ruxolitinib compared with best available therapy in patients with polycythemia vera resistant to or intolerant of hydroxyurea. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the results of the phase 2 MMY2002 trial of the anti-CD38 monoclonal antibody, daratumumab, in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. Daratumumab is a novel therapeutic human CD38 monoclonal antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses the results of the phase 3 PERSIST-1 trial of the selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3, pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Patrick I. Borgen, M.D, of the Brooklyn Breast Cancer Center talks about reducing opioids in breast cancer surgery using Bupivacaine

Charles L. Loprinzi, MD, of the Mayo Clinic discusses the management of Hot Flashes using SSRI, Gabapentin, Venlafaxine in patients with breast cancer

Charles L. Loprinzi, MD, of the Mayo Clinic reviews how Olanzapine Decreases Nausea and Vomiting in Patients With Esophageal, Head and Neck Cancer

Charles L. Loprinzi, MD, of the Mayo Clinic talks about scrambler therapy for the treatment of chemotherapy- induced peripheral neuropathy

Hope S. Rugo, MD of the UCSF Medical Center talks about the I-SPY 2 Trial and MK-2206 which shows benefit for breast cancer patients

Hope S. Rugo, MD of the UCSF Medical Center discusses numerous trials associated with checkpoint inhibitors in triple negative breast cancer

Hope S. Rugo, MD of the UCSF Medical Center discusses the state of CDK 4/6 Inhibitors for Patients with HR+/HER- Breast Cancer

Hope S. Rugo, MD of the UCSF Medical Center discusses scalp cooling system which prevented significant hair loss in 70.3% of patients with breast cancer receiving adjuvant CTX

Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882 mutations were associated with an increased risk of minimal residue disease (MRD) at the time of complete remission. DNMT3A R882 mutations may therefore be important in chemoresistance in AML. A novel genetic mouse model was used to study the role of DNMT3A R882 mutations in AML pathogenesis and chemoresistance. Presented by Olga Guryanova, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/…

Maha Hussain, MD of University of Michigan Comprehensive Cancer Center discusses Phase II Androgen Deprivation Therapy with Palbociclib

Maha Hussain, MD of the University of Michigan Comprehensive Cancer Center discusses ETS Gene Fusions as a Predictive Biomarker in Prostate Cancer

Robert J. Mayer, MD of Dana-Farber Cancer Institute discusses the results of the TAS-102 Trial for Refractory Metastatic Colorectal Cancer

HOWARD A. “SKIP” BURRIS, III, MD of Sarah Canon discusses the PD-1 Benefit in Progression Free Survival for Non-Small Cell Lung Cancer

Nicholas J. Vogelzang, MD or the University of Illinois discusses the expanded access of Radium-223 for prostate cancer patients

Nicholas J. Vogelzang, MD of the University of Illinois discusses second line bladder cancer and PD-L1 antibody

Nicholas J. Vogelzang, MD of the University of Illinois discusses a new trial Sunitinib v. PD-L1 with Bevacizumab

Nicholas J. Vogelzang, MD of the University of Illinois discusses the state of kidney cancer June 2015

Jason Luke, MD of the University of Chicago discusses Phase III Trial Pembrolizumab is Better Than Ipilimumab for Advanced Melanoma

Jason Luke, MD of the University of Chicago discusses gene expression profiling and immune signatures

Jason Luke, MD, of the University of Chicago discusses the Ipilimumab and Nivolumab Combination Study

The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free survival and relapse-free survival in younger patients with acute myeloid leukaemia (AML). Presented by Gerhard Ehninger, MD, Technical University Dresden, Dresden, Germany, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the identification of therapeutic targets for these bleeding disorders. Half of the patients had thrombocytopaenia. Several patients showed similar platelet abnormalities as the earlier reported patients with the GFI1B defect, such as decreased ?-granule numbers and/or platelet CD34 expression. The GFI1B protein is known to regulate gene expression. Almost all GFI1B variants were still active, while one had lost this function in transcription repression assays. If the new GFI1B variants are disease-causing, this would indicate a distinct molecular mechanism…

The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis. Patient-reported outcomes (PROs), which have become important for approval of new therapies, was also measured to determine whether pacritinib reduced patients symptom burden and helped them feel better. Presented by Ruben Mesa, MD, FACP, Mayo Clinic, Scottsdale, AZ, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML). Data of 2904 newly diagnosed CML patients in 20 countries or prespecified regions of Europe were recorded in a web-based registry. 94% of patients were diagnosed in early stage of disease and received treatment with imatinib according to the European LeukemiaNet (ELN) recommendations. Newer treatment options were used by patients in clinical trials or with chromosomal abnormalities. Sub-standard treatments were used rarely, but mainly in older patients. Patient survival probabilities were similar to clinical trial results after adjusting to risk profile.…

In a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), and monoclonal anti-CD20 antibody, rituximab, showed a tolerable safety profile and induced deep and durable responses, with 41% of patients achieving complete response (CR). Presented by Andrew Roberts, MB BS, PhD, FRCPA, FRACP, Royal Melbourne Hospital, Melbourne, Australia, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma, met its primary endpoints of progression-free survival and overall response rate. The two-year progression-free survival rate was 41% in the elotuzumab group versus 27% in the control group. The overall response rate in the elotuzumab group was 79% versus 66% in the control group. Presented by Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews…

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden, London, UK, discusses the phase 3 CheckMate 067 trial. The results of this trial demonstrate a superior progression-free survival of nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) regimen or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses Novel immune checkpoint inhibitors

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University talks about the CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses MET exon 14 splice variants is the oncogenic driver to target

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses the Future for PD pathway inhibitors in NSCLC

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses AZD9291 for T790M mutant EGFR is well tolerated.

LECIA SEQUIST, MD of Massachusetts General Hospital discusses TIGER X – Rociletinib for T790M EGFR mutations.

LECIA SEQUIST, MD of Massachusetts General Hospital answers the question How does Rociletinib differ from 1st generations EGFR TKIs?

LECIA SEQUIST, MD of Massachusetts General Hospital discusses ALK inhibitor Alectinib for NSCLC

This was my interview with Dr. Petros Grivas, GU medical oncologist from the Cleveland Clinic at the 2015 ASCO Annual Meeting. We discussed his work on clinical trials in GU oncology. Website for Dr. Grivas at Cleveland Clinic: http://my.clevelandclinic.org/staff_directory/staff_display?doctorid=18967

In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive stereotactic radiosurgery (SRS) alone or SRS followed by whole brain radiation therapy (WBRT). The primary endpoint of the trial was to determine the impact of SRS alone or with SRS combined with WBRT on cognitive progression. At 3 months, cognitive decline in the combination arm was 91.7% compared with 63.5% in the SRS-alone arm (P = .0007). Presented by Jan Buckner, MD, Mayo Clinic, Rochester, MN, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of death by 36% when compared with a wait-and-watch approach for therapeutic neck dissection in early, node-negative, oral squamous cell carcinoma. Presented by Anil K. D’Cruz, MS, DNB, Tata Memorial Hospital, Mumbai, India, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study of children diagnosed with cancer from 19701999 at 31 participating institutions, suggests the strategy of modifying therapy to reduce the occurrence of late effects, and promotion of early detection, is significantly reducing the observed late mortality in this population. Presented by Gregory T. Armstrong, MD, MSCE, St. Jude Children’s Research Hospital, Memphis, TN, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression-free survival (PFS) in patients with metastatic melanoma compared with ipilimumab alone. The median PFS in the group treated with the combination therapy was 11.5 months compared with 6.9 months in the nivolumab monotherapy group and 2.9 months in the ipilimumab monotherapy group. Presented by Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

LECIA SEQUIST, MD of Massachusetts General Hospital discusses LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell Carcinoma.

RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine answers the question Will immunotherapy combination regimens be both beneficial and safe for patients?

RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses the role of systemic adjuvant therapy for resected T2N0 NSCLC

DAVID ROSS CAMIDGE, MD, PHD discusses what causes mechanism resistance to Rociletinib and AZD929

A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of 106 patients whose disease worsened after at least three prior treatments, nearly one in three responded to daratumumab, and disease progression was delayed by 3.7 months, on average. The estimated one-year overall survival rate was 65%. Presented by Saad Zafar Usmani, MD, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL). Among patients for whom rituximab therapy no longer provided benefit, the average duration of remission was 29.2 months after receiving the new combination vs. 14 months after bendamustine alone. The trial was stopped early based on these encouraging results. Presented by Laurie Helen Sehn, MDCM, MPH, BC Cancer Agency, Vancouver, Canada, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments. At 24 weeks of treatment, 19.1% of patients on the pacritinib arm experienced spleen shrinkage, compared to only 4.7% of patients on the BAT arm. Presented by Ruben A. Mesa, MD, Mayo Clinic Cancer Center, Scottsdale, AZ, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that worsened despite prior therapy. At a median follow-up of 17 months, patients who received ibrutinib and BR had an 80% lower risk of disease progression or death than those who received placebo and BR. Based on this striking benefit, patients were permitted to cross over from the placebo group to receive ibrutinib. Presented by Asher Alban Akmal Chanan-Khan, MD, Mayo Clinic, Jacksonville, FL, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews…

DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver answers the question what is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?

DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver discusses the novel investigational agents for crizotinib resistant ALK-positive NSCLC.

DAVID ROSS CAMIDGE, MD, PHD, of University of Colorado Denver discusses the role of T790M mutations in resistance to first generation EGFR TKIs and what role agents such as Rociletinib may have in the future.

This was my discussion at the ASCO Annual Meeting June 1, 2015 with Dr. Petros Grivas, medical oncologist specializing in prostate and bladder cancers at the Cleveland Clinic. He discusses his work in translating genomic profiling to the clinic through clinical trials. http://my.clevelandclinic.org/staff_directory/staff_display?doctorid=18967

Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the results of the phase I part of the study, eight (19%) of the 42 evaluable patients responded to the anti-PD-1 antibody with tumour reduction beyond 30%. More importantly, the responses have been durable and surpassed 12 months in four patients. The overall survival rate at 12 months was 62%. Presented by Anthony B. El-Khoueiry, MD, University of Southern California Norris, Comprehensive Cancer Center, Los Angeles, CA at ASCO 2015, Chicago, IL European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC). Among patients with advanced disease that worsened after receiving platinum-based chemotherapy, those treated with nivolumab lived on average three months longer than those treated with docetaxel chemotherapy. Presented at ASCO 2015, Chicago, IL by Professor Luis Paz-Ares, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the role of MET in NSCLC and why earlier TKIs and antibodies have been disappointing.

Dr. Mark Kris of Memorial Sloan Kettering discusses phase II study of cabozantinib in RET rearranged NSCLC at the annual meeting in Chicago

This was my interview with Dr. Alok Khorana of the Cleveland Clinic at the ASCO Annual Meeting on May 30, 2015. Earlier that day, there was a presentation demonstrating significant benefit using pembrolizumab in patients with microsatellite unstable (MSI) tumors.

This is my conversation with Dr. Alok Khorana, Director of the GI Malignancy Program at the Cleveland Clinic. Dr. Khorana will be presenting an abstract Saturday, May 30, 2015 at the ASCO Annual Meeting on this research. He discusses incorporation of global oncology approaches to trials studying venous thrombemboli in GI cancers, and upcoming trials in this area.

Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.

Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the Lung Cancer Mutation Consortium and the role of Next Generation Sequencing in NSCLC.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Eleni Efstathiou (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses prospective management strategies for prostate cancer. Topics of interest include radiotherapy, androgen-deprivation therapy (ADT), inhibitors of nuclear export and androgen-signalling inhibitors. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) summarises the status of poly (ADP-ribose) polymerase (PARP) inhibitors in preclinical and clinical development for the treatment of breast cancer. Prof. Dr. med. Fasching explains the design of the EMBRACA study, which is a 2:1 randomised phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universitä?t Erlangen-Nürnberg, Erlangen, Germany) discuss the functions of the BRCA1 and BRCA2 proteins in response to DNA damage in BRCA-related breast cancer. The development of molecular profiling in BRCA-related breast cancer has allowed an increasingly accurate assessment of tumour biology and should allow us to utilise this mutation in the treatment of the cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews what is known about the functions of poly (ADP-ribose) polymerase (PARP) and outlines the rational development of PARP inhibitors as anticancer agents for tumours associated with BRCA gene mutations. Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) describes targeting the defect in DNA repair in BRCA-related breast cancer with poly (ADP-ribose) polymerase (PARP) inhibitors. In BRCA-related breast cancer cells, DNA double-strand break repair is impaired, so inhibition of PARP, which has a role in DNA single-strand break repair, increases the susceptibility for additional DNA damage and cell death. Accordingly, PARP inhibitors may be important novel therapeutic agents for the treatment of BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews…

Michael Kolodziej, MD, National Medical Director, Oncology Strategies, Aetna, Inc. talks about Next Steps in Oncology Payment Reform for Established Provider & Payer Teams

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) discuss the clinical development of the poly (ADP-ribose) polymerase (PARP) inhibitor, talazoparib, for the treatment of BRCA-related breast cancer. The ongoing EMBRACA study is a 2:1 phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Roberta L. Buell, Principal, OnPoint Oncology, LLC discusses the Top 2015 Reimbursement Issues & ICD-10 Update from the Coding Mistress

Robert Baird Jr., RN, MSA, Chief Executive Officer, Dayton Physicians Network discusses Payment Reform for Established Provider & Payer Teams

David Eagle discusses what Are the Key Cost Drivers of Cancer Care moving forward at the COA meeting in Orlando

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews the medical and social implications of BRCA gene mutation testing. Women with a deleterious BRCA gene mutation can be offered various management options, including prophylactic surgery and chemoprevention, to reduce the risk of breast cancer development. It is important for clinicians to understand and respond to a patients subjective experience during the clinical management process. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

James W. Hodge, PhD, MBA, Investigator, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Center talks about Perspective from the NCI: Importance of Immunotherapy Trials

Phil Johnson, MS, RPh, Director of Pharmacy (Retired), Moffitt Cancer Center talks about Biosimilar Overview: Opportunities & Issues

Jeff Mortier talks about the latest information about the Cancer Payment Reform Bill.

At the Myeloma 2015 meeting, Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on immunotherapies that are in clinical development for the treatment of multiple myeloma. Novel immune-based combinations that seem particularly noteworthy are discussed. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas, Fayetteville, AR) and Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) on studies involving new tumour biology-guided strategies for treating multiple myeloma (MM). They focus on immune modulators and inhibitors of critical signalling pathways in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses the design and rationale of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey. The MAGIC survey is an evaluation of the heterogeneity of the treatment decisions made by clinicians regarding the need for adjuvant chemotherapy in breast cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Person they are interveiwng, their credentials

Bobbi Buell from onPoint Oncology talks about ICD-10 and what it means to oncology payments

Keith L. Knutson, PhD, Director, Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida Practical Immuno-Oncology 101 for Oncologists & Nurses

Laura Stevens, Program Director for CMMI Come Home Project talks about the Come Home Project and how it works.

Ricky Newton of COA talks about the new COPA program called Community Oncology Pharmacy Association at the COA annual meeting in Orlando, FL.

Ted Okon and Peter Yu, MD discuss new legislative issues associated with oncology for 2015 at the COA annual meeting in Orlando, FL.

Bo Gamble & Carol Murtaugh talk about What does it take to become a Oncology Medical Home at the annual Community Oncology Alliance meeting in Orlando, 2015

On the first day of the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on new approaches for treating multiple myeloma (MM). Topics include early intervention for smoldering MM, treatment strategies for high-risk MM, and novel drugs in clinical development that may improve patient outcomes in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the opportunities at the 14th St. Gallen International Breast Cancer Conference 2015 to develop new guidelines in breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Véronique Diéras (Institut Curie, Paris, France) discusses the phase 2 PALOMA-1 study of the cyclin-dependent kinase 4/6 inhibitor, palbociclib, in combination with letrozole versus letrozole alone as first-line treatment for women with oestrogen receptor-positive (ER+), HER2-negative (HER2-), advanced breast cancer. The addition of palbociclib to letrozole significantly improved progression-free survival in this patient population. A phase 3 trial is in progress. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Kidney Cancer Organization Welcome Lyon Meeting 2015 Carolyn Konosky

Kidney Cancer Meeting Lyon, France 2015: Immunotherapy versus targeted treatments in metastatic renal cell carcinoma:The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I

Kidney Cancer Meeting Lyon, France 2015: Functional imaging in renal cancer: a 10 year history. Tom Powles Barts Cancer Institute ECMC, UCH and Royal Free Hospitals: London Cancer Queen Mary University of London

Kidney Cancer Meeting Lyon, France 2015: Treatment beyond second line Camillo Porta Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy

Kidney Cancer Meeting Lyon, France 2015: Will Immunotherapy Marginalise Targeted Therapy to a Salvage Role by 2020? Tim Eisen University of Cambridge

Kidney Cancer Meeting Lyon, France 2015: Have Results of Recent Randomized Trials Changed the Role of mTOR Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France

Kidney Cancer Meeting Lyon, France 2015: What Have Sequencing Trials Taught Us?

Kidney Cancer Meeting Lyon, France 2015: Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D. Radiation Oncologist

Kidney Cancer Meeting Lyon, France 2015: New target:FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute

Kidney Cancer Meeting Lyon, France 2015: 1st line treatment:what has changed in the last 2 years? Martin Gore PhD FRCP Royal Marsden Hospital Institute of Cancer Research London

Kidney Cancer Meeting Lyon, France 2015: LOCAL TREATMENT FOR LUNG ET LIVER METASTASES SURGERY/ABLATION IS THE GOLD STANDARD – Alain Ravaud, MD PhD Bordeaux University Hospital, Bordeaux, France

Kidney Cancer Meeting Lyon, France 2015: Toxicity from Checkpoint Inhibitors James LarkinFRCP PhD

Kidney Cancer Meeting Lyon, France 2015: TKI drug interaction: what else do I need to know for my patient for anti-VEGF? Romano Danesi, MD, PhD Professor of Pharmacology Department of Clinical and Experimental Medicine University of Pisa Medical School, Italy

Kidney Cancer Meeting Lyon, France 2015: Mechanisms and management of hypertension associated with anti-VEGF-treatment Stephane Ederhy Service de Cardiologie Hopital Saint Antoine Paris, France

Kidney Cancer Meeting Lyon, France 2015: Skin Side Effects Associated with Kidney Cancer Treatment Christiane Thallinger, MD University of Vienna, Department of Oncology, General Hospital vienna

Kidney Cancer Meeting Lyon, France 2015: Vaccines for RCC: Rationale and Clinical Update Hans Hammers M.D. / Ph.D. Assistant Professor: Medical Oncology, Chemical Therapeutics Johns Hopkins Kimmel Cancer Center

Kidney Cancer Meeting Lyon, France 2015: New Targets to Reverse VEGF Resistance Prof. Eric Raymond, MD, PhD Head of Medical Oncology UNIL-CHUV Lausanne – Switzerland

Kidney Cancer Meeting Lyon, France 2015: T-Cell Checkpoints in RCC:Musings from a non-immunologist Primo N. Lara, Jr., M.D. Professor of Medicine University of California Davis School of Medicine Associate Director for Translational Research UC Davis Comprehensive Cancer Center Sacramento, CA, USA

Kidney Cancer Meeting Lyon, France 2015: Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON

Kidney Cancer Meeting Lyon, France 2015: Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? The Oncologists view Viktor Grünwald

Kidney Cancer Meeting Lyon, France 2015:Have Medical Oncologist and Urologist Different Views on Cytoreductive Nephrectomy? Axel Bex, The Netherlands Cancer Institute Amsterdam, The Netherlands

Kidney Cancer Meeting Lyon, France 2015: Should we push for even more minimal invasive and conservative approaches in kidney cancer? The view of the medical oncologist. Manuela Schmidinger, Medical University of Vienna Austria

Kidney Cancer Meeting Lyon, France 2015: Should we push even more for minimal invasive and conservative approaches in kidney cancer? Antonio Alcaraz Hospital Clínic Barcelona

Kidney Cancer Meeting Lyon, France 2015: Should We Now Biopsy Every Single Renal Tumor Before Treating? Bernard Escudier Institut Gustave Roussy Villejuif, France

Kidney Cancer Meeting Lyon, France 2015: SHOULD WE NOW BIOPSY EVERY SINGLE RENAL TUMOR BEFORE TREATING ? Alessandro VOLPE, M.D. University of Eastern Piedmont – Maggiore della Carità Hospital Novara, Italy

Kidney Cancer Meeting Lyon, France 2015: John Fitzpatrick Tribute: Life in the Fast Lane

Kidney Cancer Meeting Lyon, France 2015: Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology, MD Anderson

Kidney Cancer Meeting Lyon, France 2015: Clinical Relevance of Cancer Gene, James Brugarolas M.D., Ph.D. Kidney Cancer Program Leader Virginia Murchison Linthicum Endowed Scholar Associate Professor of Internal Medicine & Developmental Biology University of Texas Southwestern Medical Center

Kidney Cancer Meeting Lyon, France 2015: Tribute to Pieter De Mulder by Hein Van Poppel Professor and Chairman UZ Leuven Adjunct Secretary General EAU. Nephron Sparing SurgeryPast, Present and Future

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the key challenges in the manufacture, development and approval of biosimilars for breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses his highlights from the 14th St. Gallen International Breast Cancer Conference 2015. In addition, he provides an update on the novel combination antiemetic, netupitant and palonosetron (NEPA), for the prevention of chemotherapy-induced nausea and vomiting, and prospective opportunities and challenges for managing breast cancers with a focus on adjuvant therapies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Geoff Lindeman (The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) discusses the importance of the new therapeutic targets of BCL-2, BH3 mimetics, in oestrogen receptor-positive (ER+) breast cancer, including the challenges in the development process and use in clinical practice. Preclinical models of ER+ breast cancer demonstrate that BH3 mimetics combined with tamoxifen improves the effectiveness of hormone therapy. Clinical studies of the BH3 mimetic, ABT-199, are beginning in ER+ breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding of the current state of the biosimilar market as well as future challenges of the development and regulation of biosimilars. Biosimilars, which are biological products that demonstrate no clinically meaningful differences to an approved biological product, are currently approved in several areas of the world, and the biosimilars development pipeline is relatively large.European Medical JournalWebsite: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

This is my interview with Jeri Francoeur, Breast Cancer Patient Advocate, breast cancer survivor, and President of the Susan G Komen Chapter in Central Florida.

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development of the cyclin-dependent kinases (CDKs) 4 and 6 inhibitor, palbociclib, for breast cancer treatment. The phase 2 PALOMA-1 trial showed that the addition of palbociclib to letrozole significantly increased the progression-free survival versus letrozole alone in oestrogen receptor-positive, HER2-negative metastatic breast cancer. Subsequently, palbociclib received accelerated approval as frontline treatment for this patient population. Current trials are investigating palbociclib in other areas of breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference (SG-BCC) 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how mining big data can complement research approaches and improve patient care in cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses his study on the influence of cut points in the proliferation marker, Ki67, for clinical decision making in breast cancer patients, and suggests that Ki67 could be used as a continuous marker in this setting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent advances in neoadjuvant therapy for breast cancer, including the rationale for the use of the surrogate endpoint for survival, pathological complete response (pCR), in neoadjuvant studies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses the opportunities and challenges of developing new agents for breast cancer treatment, including optimising the use of drugs that target genetically defined breast cancer and the integration of these approaches. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the use of electronic medical records as a source of ‘big data’ that could potentially transform healthcare. CancerLinQ is one initiative that is aiming to aggregate and analyse data collected from patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses the clinical relevance of a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results. Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses how prospective randomised trials in breast cancer treatment can adapt to the modern healthcare landscape. There is a promising potential for electronic medical records to provide data that is complementary to randomised trials, thereby improving research approaches in cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss recent advances in the management of patients with mantle cell lymphoma, including maintenance treatment and the development of personalised medicine. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discuss novel therapies and the future of chemotherapy-based regimens for the management of patients with relapsed or refractory mantle cell lymphoma. Part 1: http://www.oncologytube.com/v/1034690/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment Part 2: http://www.oncologytube.com/v/1034691/ash-2014-prof-john-gribben-and-prof-marek-trn-n-discuss-recent-advances-in-mantle-cell-lymphoma-treatment This programme has been supported by sponsorship from Celgene European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

What should be the protocol for a rising PSA in an undiagnosed patient? Dr. Geo Espinosa of NYU-Langone Medical Center lays out the desired pathway in the context of patient-centric holistic uro-oncology.

Dr Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) provides an overview of immune approaches for the treatment of breast cancer at the 14th St. Gallen International Breast Cancer Conference 2015, including: The prognostic influence of tumour-infiltrating lymphocytes; Ongoing clinical trials of targeted therapies that modulate the immune system the PD-1 inhibitor, pembrolizumab, for triple-negative breast cancer, and the combination of trastuzumab and PD1-inhibitor for HER2-positive breast cancer; Tumour antigen cancer vaccines and ductal carcinoma in situ (DCIS). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Giuseppe Viale (European Institute of Oncology and University of Milan, Milan, Italy) discusses personalised genomic medicine for breast cancer, including the challenges of designing meaningful clinical trials to identify novel and relevant genetic disease biomarkers and the requirement for collaboration by multidisciplinary teams. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Geo Espinosa of NYU-Langone Medical Center explains the concept of Integrative Urology – the union of traditional and complementary standards of care to provide a more holistic, patient-centric modality.